Endothelial cells: the guarantee is written in the supplier medium, and it is not portable

Endothelial cells are the cheapest human primary cell on this catalogue and the one where an under-specified purchase order does the most damage. A vial of HUVEC lists for less than a third of a vial of iPSC-derived astrocytes, which encourages buyers to treat it as a commodity. It is not a commodity, because the thing that determines whether the vial supports your experiment, how many population doublings remain in it, and under whose conditions, is published by some suppliers, not by others, and is void outside the supplier’s own medium in every case.

The clearest illustration in the market is a pair of SKUs from one company, and it is worth reading before any price is compared.

The price and specification table

Read the Lonza rows together. Both are HUVEC. One is guaranteed for fifteen population doublings. The other is guaranteed for five, arrives at passage 3, contains ten million cells per vial, and carries an explicit statement from the supplier that it is not suggested to further expand, subculture or bank the cells after thawing.

Twenty times the cells and a third of the remaining doublings. That is a different product for a different experiment rather than a better or worse one, and it is the single clearest demonstration in this market that a cell price buys a defined quantity of remaining biology, not a quantity of cells.

Note also what is missing: Lonza publishes the most useful specification in the category and does not publish a price on the pages checked on 2026-09-01. We do not estimate one.

The doubling guarantee is not portable, and that is the whole point

Every population doubling guarantee in this category is conditional on the supplier’s own media, reagents and protocol. ScienCell guarantees fifteen doublings under ScienCell’s conditions. PromoCell guarantees more than fifteen without antibiotics, which is a specific and demanding condition. Lonza states its per-product guarantees against its own systems.

Three consequences that are routinely missed at the purchase order stage.

The medium cost is part of the cell cost. A $266.00 vial run in a $300 bottle of the supplier’s medium is a $566 purchase, and switching to a cheaper medium does not save $300, it voids the specification you were paying for. Compare cells-plus-medium against cells-plus-medium.

A guarantee expressed in doublings is not a guarantee expressed in passages. Doublings and passages are only interchangeable at a fixed split ratio and a fixed confluence at harvest. If your laboratory splits differently from the supplier’s protocol, you will consume the guarantee at a different rate than you expect. The distinction is set out in passage number and population doublings.

The guarantee describes proliferative capacity, not phenotype. A cell that is still dividing is not necessarily a cell that still behaves like an endothelium. Metabolomic work on HUVEC across replicative senescence (PMC7066908) documents that the metabolic state shifts as the cells approach the end of their proliferative life. Work inducing senescence in HUVEC by pesticide exposure (PMC12946610) demonstrates the same endpoint reached by a different route. The practical rule is to plan the experiment inside the guarantee with headroom, not up to its edge.

Pooled or single donor, and what pre-screening is actually buying

Cell Applications lists standard HUVEC at $266.00 and a pre-screened HUVEC lot at $536.00, both captured live from the public store API on 2026-09-01. That is a 102 percent premium, and it is the largest pre-screening premium in that supplier’s catalogue, for context, the same supplier’s pre-screening premium on myoblasts is around 15 percent.

That gap is a signal about the category rather than a pricing quirk. Donor-to-donor variation in endothelial function is large. Tube formation, permeability, and response to a stimulus vary enough between primary lots that an unscreened lot can swallow a real effect or manufacture a false one. A pre-screened lot has been functionally characterised against a defined assay before release, and for endothelial work that is worth substantially more than it is for a cell type whose functional readout is less variable.

The decision is straightforward once framed correctly:

Buy a pre-screened lot when the endothelial functional readout is the experiment, permeability, tube formation, barrier integrity, adhesion, and when a failed run costs more than $270. On a multi-week barrier experiment it always does.

Buy the standard lot when the endothelium is scenery rather than subject: a supporting layer in a co-culture where you are measuring something else, or a rehearsal run to qualify a protocol.

Buy pooled when you want to average donor variation away and your question is about a population response rather than an individual. Buy single-donor when you need to attribute a phenotype to a genotype or a disease state, or when your design compares donors. Lonza catalogues pooled and single-donor HUVEC as separate SKUs, and also catalogues Type I and Type II diabetic donor variants where the disease state is the requirement.

The mistake to avoid is buying a pooled lot and then reasoning about it as though it were a person.

Vessel and donor origin is a gating specification

“Endothelial cell” is a family, not a product, and the members are not substitutes.

HUVEC (umbilical vein). The default, the cheapest, the most published. Macrovascular, venous, neonatal. A modified isolation and culture protocol published in 2025 (PMC12423704) is a reminder that even this most standard of preparations still has method variation worth asking about. HUVEC are the right answer for a large amount of vascular biology and the wrong answer whenever tissue-specific endothelial identity matters.

Dermal microvascular. Different from macrovascular endothelium in morphology, marker profile and barrier behaviour. If your model is skin, a microvascular source is a specification, not an upgrade.

Brain microvascular and blood-brain barrier endothelium. This is where the substitution error is most expensive. Building a barrier model on HUVEC because they were cheaper produces a barrier with the wrong tightness. Published iPSC routes to blood-brain barrier endothelial cells exist precisely because primary macrovascular cells do not reproduce the phenotype, a simplified fully defined differentiation scheme (PMC6565873) and an accelerated protocol (PMC5390351) are both published. HUVEC do appear in blood-brain barrier model work, but as a component in a stromal interaction study (PMC12153851) rather than as a claim to be barrier endothelium. Know which of those two things you are doing.

The full account of building a barrier model, including which cell choices are defensible, is in building a blood-brain barrier model.

The pathogen panel: named or not named

This is a specification that separates suppliers cleanly and costs nothing to check.

ScienCell publishes a named panel on every primary product page: negative for HIV-1, HBV, HCV, mycoplasma, bacteria, yeast and fungi. PromoCell publishes the broadest itemised panel found in this survey: HIV-1/2, HBV, HCV, HTLV-1/2, fungi, bacteria and mycoplasma. Both name the agents.

A supplier that states “virus tested” without itemising is making a weaker claim that cannot be compared against either of those. It is not necessarily a worse product; it is an unspecified one. Ask for the itemised panel in writing before the order, and if your institution has biosafety requirements for incoming human primary material, check the panel against them rather than assuming overlap.

The cheapest saving in the category

Endothelial vials are cheap enough that the largest available saving is not in the vial price at all.

It is in not consuming the guarantee on rehearsals. A lot bought with fifteen doublings and spent qualifying a coating protocol, training a technician on a permeability assay and debugging an imaging pipeline arrives at the actual experiment with a fraction of its useful life left, in a state the supplier no longer guarantees.

Two ways to avoid it, both cheaper than buying a second lot:

• Rehearse on a lower-value lot. A standard $266.00 lot for method development and a $536.00 pre-screened lot for the experiment costs less than two pre-screened lots, and it puts the characterised material where the data is.
• Plan the doubling budget on paper first. Count the expansions your protocol requires between thaw and readout, at your split ratio, and check that number against the guarantee before you order. This takes ten minutes and it is the most commonly skipped step in primary cell procurement.

QC checklist

• Lot-specific certificate of analysis, reviewed before you commit.
• Passage number at ship, stated as a number rather than as “low passage”.
• Guaranteed remaining population doublings at that passage, and the specific media, reagents and protocol the guarantee is conditional on, by catalogue number.
• Post-thaw viability specification and the assay used.
• Whether the stated cell count is at freeze or viable post-thaw.
• Itemised pathogen panel by agent name, not a “tested” claim.
• Pooled or single donor, and for pooled lots the number of donors contributing.
• Donor demographics, age, sex, and disease state where relevant.
• For pre-screened lots: the assay the lot was screened against, and the numeric result for this lot rather than a typical value.
• Mycoplasma and sterility release testing with the method named.
• Shipping format and receiving procedure, and the maximum acceptable hold time on receipt.
• Any supplier statement restricting further expansion, subculture or banking, which exists on at least one HUVEC product in this market and is easy to miss.

Specification checklist for an endothelial cell quote

• Vessel and donor origin: umbilical vein, dermal microvascular, brain microvascular, or another named bed. State it explicitly; do not write “endothelial cells”.
• Macrovascular or microvascular, stated separately from the anatomical site.
• Pooled versus single-donor lot, with a reason attached, because the reason determines the answer.
• Passage at ship and doublings required for your protocol, worked out against your split ratio before the enquiry goes out.
• Standard or pre-screened, and if pre-screened, the assay you want it screened against.
• Disease-state donor requirement, for example Type I or Type II diabetic, where the phenotype is the point.
• Medium and supplement package, and confirmation of which formulation the doubling guarantee attaches to.
• Coating requirement and whether it is included.
• Total cells required across the programme, in the counting convention the supplier uses, with the vial configuration that follows. Note the existence of high-cell-count, low-doubling vials before assuming a bigger vial is a better deal.
• Itemised pathogen panel required by your biosafety committee.
• Licence terms for anything downstream that will be sold rather than published.

Where to go next

The datasheet, unit, lead time and QC scope, is at human-endothelial-cells. If the destination is a barrier model, building a blood-brain barrier model covers which endothelial source is defensible for which claim. The mechanics of the doubling guarantee are in passage number and population doublings, and the supplier landscape is in primary human cell suppliers.

How we can help

We re-verify these figures and we resell nothing. Tell us the vessel bed, the assay, the doubling budget your protocol implies and whether the readout is the endothelium itself, and we will source quotes, put the doubling guarantee and its conditional medium next to each price, obtain the itemised pathogen panel in writing, and flag any supplier statement restricting expansion before you build a seed train that is not permitted.

For a single standard HUVEC vial from a supplier with a public storefront, buy it directly. That is a checkout, not a sourcing problem.